Fundraising FoxInvus — 2024 Investments
7 investments dated 2024 · listed companies and verified rows first · show all
Seaport Therapeutics develops therapeutics and medicines.
BiotechMental HealthBoston, US
Daphne Zohar(Founder, CEO & Board Member)inSteven Paul, M.D.(Founder, Board Chair)inMichael Chen, Ph.D.(Co-Founder, Chief Scientific Officer)Michael Chen(Executive Officer)inLana Gladstein(Executive Officer)inAntony Loebel(Executive Officer)in
Co-investorsARCH Venture PartnersForesite CapitalGeneral AtlanticHAWKTAILPureTech HealthSofinnova Ventures+4 more
Cardurion is a cardiovascular disease-focused company developing therapeutics, with a pipeline advanced through clinical development, trial design, regulatory affairs, and commercialization.
BiotechDigital HealthHealthtechMedical DevicesBurlington, US
Michael E. Mendelsohn(Founder and Chief Strategy Officer)inMichael Mendelsohn(Executive Officer, Director)
BoardEvan Rachlin(Director)Peter Lawrence(Executive Officer, Director)Edward Mathers(Director)Adam Koppel(Director)in
Co-investorsBain CapitalAscenta CapitalBain Capital Life SciencesDeepWork CapitalDelos CapitalDigitalis Ventures+7 more
City Therapeutics develops RNAi-based medicines targeting rare, specialty, and prevalent diseases using engineered trigger molecules and precision delivery ligands.
BiotechMedical DevicesCambridge, US
Mark Keating, MD(Co-founder)Kotaro Nakanishi, PhD(Co-founder)Yukihide Tomari, PhD(Co-founder)Phillip Zamore, PhD(Co-founder)Andy Orth(Chief Executive Officer)in
Co-investorsAN Venture PartnersARCH Venture PartnersSofinnova VenturesViking GlobalAltitude Ventures Management, LlcCasdin Capital+5 more
NextPoint is a precision therapeutics company developing cancer treatments targeting the B7-H7/HHLA2 axis, including a T-cell engager, an antibody-drug conjugate with proprietary linker technology, and a multi-functional checkpoint inhibitor.
BiotechHealthtechAustin, US
Gordon Freeman(Scientific Founder)XingXing Zang(Scientific Founder)inIvan Cheung(Chief Executive Officer)inLeena Gandhi(Chief Medical Officer)inTatiana Novobrantseva(Chief Scientific Officer)inAxel Hoos(Director)
Co-investorsCatalio Capital Management, LPMPM BioImpactSanofi VenturesCatalio Capital ManagementLeaps by BayerSixty Degree Capital
Sensorion is a French clinical-stage biopharmaceutical company founded in 2009 in Montpellier that develops gene-therapy and small-molecule treatments for inner-ear disorders like genetic deafness and tinnitus.
Co-investorsSofinnova PartnersREDMILESanofi Ventures
Triveni Bio develops genetics-informed antibody therapeutics aimed at treating complex immunology and inflammation (I&I) diseases.
BiotechDigital HealthHealthtech
Vishal Patelin
Co-investorsAscenta CapitalAtlas VentureBorealis VenturesBorealis VenturesMagnetic VenturesOrbiMed+4 more
Zenflow develops a minimally invasive medical device, the Spring implant, to relieve urinary obstruction caused by benign prostatic hyperplasia (BPH) in men.
HardwareHealthtechMedical DevicesSan Francisco, US
Shreya Mehta(CTO)inNick Damiano(CEO)inJohn Beck(Executive Officer)in
BoardBryan Kim(Director)Robert Weisskoff(Director)inBlayne Roeder(Director)
Co-investorsAstiaCloudStone CapitalDorm RoomF-Prime CapitalShangBay Capital LLCY Combinator+15 more
Rows marked “SEC filing” are inferred from directors named on the company's SEC Form D — public regulatory data, not a portfolio list published by the firm.